Last $62,700 COP
Change Today 0.00 / 0.00%
Volume 0.0
PFE On Other Exchanges
Symbol
Exchange
New York
Xetra
Mexico
SIX Swiss Ex
Stockholm
London
Sao Paulo
Bogota
As of 4:00 PM 04/1/14 All times are local (Market data is delayed by at least 15 minutes).

pfizer inc (PFE) Snapshot

Open
--
Previous Close
$62,700
Day High
--
Day Low
--
52 Week High
04/1/14 - $62,700
52 Week Low
11/6/13 - $60,040
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
6.4B
EX-Date
07/30/14
P/E TM
--
Dividend
$1.04
Dividend Yield
3.10%
Current Stock Chart for PFIZER INC (PFE)

pfizer inc (PFE) Related Businessweek News

View More BusinessWeek News

pfizer inc (PFE) Details

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines, and various consumer healthcare products. The company’s Primary Care segment offers prescription pharmaceutical products primarily prescribed by primary-care physicians for various therapeutic and disease areas comprising Alzheimer’s disease, cardiovascular, erectile dysfunction, genitourinary, major depressive disorder, pain, respiratory, and smoking cessation. Its Specialty Care and Oncology segment provides prescription pharmaceutical products for anti-infectives, endocrine disorders, hemophilia, inflammation, ophthalmology, pulmonary arterial hypertension, specialty neuroscience, and vaccines, as well as oncology and oncology-related illnesses. The company’s Established Products and Emerging Markets segment offers prescription pharmaceutical products that had lost patent protection or marketing exclusivity in certain countries and/or regions, as well as sold in emerging markets, including Asia, Latin America, the Middle East, Eastern Europe, Africa, Turkey, and Central Europe. Its Consumer Healthcare segment provides non-prescription products in a range of therapeutic categories, such as dietary supplements, pain management, respiratory, and personal care. The company also offers Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Norvasc, Sutent, and the Premarin family of products; and consumer healthcare products under the Advil, Caltrate, Centrum, ChapStick, Emergen-C, Preparation H, and Robitussin brands. It serves wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, and grocery and convenience stores. It has strategic alliance with CliniWorks (Israel) Ltd. to develop population health management platform with advanced analytics and patient care capabilities. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

77,700 Employees
Last Reported Date: 02/28/14
Founded in 1849

pfizer inc (PFE) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.8M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $1.2M
President of Worldwide Research and Developme...
Total Annual Compensation: $1.1M
Group President of Global Innovative Pharma B...
Total Annual Compensation: $926.3K
Group President of Global Established Pharma ...
Total Annual Compensation: $810.1K
Compensation as of Fiscal Year 2013.

pfizer inc (PFE) Key Developments

Pfizer Inc. Wins Dismissal of Investor Suit Against Celebrex and Bextra

Pfizer Inc. won a dismissal of a decade-long shareholder class action lawsuit which claimed the company misled investors about the safety of its pain-relieving drugs Celebrex and Bextra. U.S. District Judge Laura Taylor Swain in New York handed down the ruling ahead of an expected September 9, 2014 trial. The class action lawsuit was launched in 2004 and it covers investors who acquire PFE shares between October 31, 2000 and October 19, 2005.

CliniWorks (Israel) Ltd. Forms a Strategic Alliance with Pfizer to Develop Population Health Management Platform with Advanced Analytics and Patient Care Capabilities

CliniWorks announced a strategic alliance between its I subsidiary CliniWorks (Israel) Ltd. and Pfizer Inc. to jointly advance the parties' respective capabilities in working with healthcare provider organizations to identify and close clinical or quality gaps to improve population health. The two companies are partnering to develop a population health management platform solution that leverages CliniWorks' technologies in disparate data aggregation and Natural Language Processing (which interprets free text information) of de-identified healthcare data and Pfizer's scientific, clinical and disease expertise. This platform will aim to enable large medical groups and integrated delivery system institutions to deliver near real-time and more efficient and effective quality healthcare, as well as improve patient engagement or activation, reaching the Centers for Medicare and Medicaid (CMS) Triple Aim. The development work will be partially supported by a grant received by CliniWorks and Pfizer from the BIRD Foundation.

GlycoMimetics, Pfizer Sign Agreement with FDA Under a Special Protocol Assessment for Phase 3 Clinical Trial of Rivipansel

GlycoMimetics said that Pfizer Inc., the company's sponsor for its ongoing clinical development for rivipansel (GMI-1070), has reached agreement with the U.S. Food & Drug Administration (FDA) under a special protocol assessment (SPA) for a Phase 3 trial for the drug. A SPA is a written agreement between a trial's sponsor and the FDA regarding the design, endpoints and statistical analysis approach of a Phase 3 clinical trial, results from which could potentially support approval of a New Drug Application (NDA). Rivipansel is being developed as a potential therapy for treatment of patients with sickle cell disease who are hospitalized for vaso-occlusive crisis (VOC). It has previously received both Orphan Drug and Fast Track status for the treatment of VOC from the FDA. Pfizer plans to begin the Phase 3 program before the end of 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PFE:CB $62,700.00 COP 0.00

PFE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $144.31 USD +0.42
Bayer AG €101.21 EUR 0.00
Gilead Sciences Inc $88.73 USD -0.21
Mondelez International Inc $38.42 USD +0.43
Procter & Gamble Co/The $81.16 USD -0.45
View Industry Companies
 

Industry Analysis

PFE

Industry Average

Valuation PFE Industry Range
Price/Earnings 18.3x
Price/Sales 3.8x
Price/Book 2.5x
Price/Cash Flow 7.3x
TEV/Sales 2.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PFIZER INC, please visit www.pfizer.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.